In this study, in the form of a drug delivery formulation, synthetic miR-204 was again confirmed to be able to inhibit tumor growth in vitro and in vivo, and the expressions of BCL2 and RAB22A were significantly down-regulated in tumor tissue. Here, BCL2 is linked to neoplasm.